Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy
Ben-Ami E, et al. Ann Oncol. 2016; 27: 1794-1799
横浜労災病院消化器内科　地口　学

Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor
Komatsu Y, et al. Jpn J Clin Oncol. 2015; 45: 1016-1022
北海道大学病院腫瘍センター　小松嘉人

Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis
Guller U, et al. Gastric Cancer. 2017; 20: 49-60
大阪大学大学院医学研究科　外科学講座消化器外科　菅生貴仁

Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic
Boikos SA, et al. JAMA Oncol. 2016; 2: 922-928
九州大学病院　病理診断科　山元英崇

Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry
Sato S, et al. Surg Today. 2017; 47: 58-64
静岡県立総合病院　消化器センター　食道胃外科　佐藤真輔